Search
Canagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type
Mixtures: VOKANAMET TM TABLETAS RECUBIERTAS 50 / 1000MGFomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnIt was discovered by scientists at the National Institutes of Health (NIH) and was first developed by _Isis Pharmaceuticals_ and subsequently licensed to _Novartis_ [A31990]. … The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development
Tebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigationalto be approved by the FDA. … This approval marks the first bispecific T cell engager to be approved by the FDA to treat a solid tumour and being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma
Categories: Bispecific gp100 Peptide-HLA-directed CD3 T Cell EngagerZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigational[A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. … L10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug.
Bendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawna small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation. … Bendazac, however, has since been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity [A39891, A39892, A39893, L4778] in patients although
Dapiprazole
go.drugbank.com/drugs/DB00298ApprovedIt is found in ophthalmic solutions used to reverse mydriasis after an eye examination.
Synonyms: 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridineScopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. … [A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.
Simvastatin
go.drugbank.com/drugs/DB00641ApprovedInvestigational[A181409,A181535,A181538,A1793] Potency is thought to correlate to tissue permeability as the more lipophilic statins such as simvastatin are thought to enter endothelial cells by passive diffusion, as … It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the
Tremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tumour growth. … [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. … [A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's